Dermatitis News

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Henry W. Lim, MD, FAAD, discusses the economic burden of skin disease in the United States.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Alexis, MD, MPH, discusses treatment for disorders of pigmentation.

Late-breaking research presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida, included vitiligo and research treatment.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Henry W. Lim, MD, FAAD, discusses highlights from the meeting.

Patients with epidermolysis bullosa simplex treated with topical diacerein 1% ointment had long-term reduction of blister formation compared with placebo treatment, according to research presented by Johann Bauer, MD, MBA, HCM, at the American Academy of Dermatology Annual Meeting in Orlando, Fla.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Amy J. McMichael, MD, FAAD, discusses seborrheic dermatitis and hair fragility in African-American women.

ORLANDO, Fla. — Microneedling with tranexamic acid solution was an effective treatment for women with erythematotelangiectatic rosacea, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Vicki Lawrence discusses her diagnosis of chronic idiopathic urticaria and the patient educational campaign that she represents.

ATLANTA — Bola Akinlade, MD, MBA, FACP, clinical program leader, Regeneron, provided an update on studies involving dupilumab for the management of some dermatologic conditions at the annual meeting of the American Academy of Allergy, Asthma & Immunology.

ORLANDO, Fla. —In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his late-breaking research presentation on Dupixent with concomitant topical corticosteroids to treat moderate-to-severe atopic dermatitis.